BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thakral P, Sen I, Pant V, Gupta SK, Dureja S, Kumari J, Kumar S, Un P, Malasani V. Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM). Br J Radiol 2018;91:20170172. [PMID: 30028180 DOI: 10.1259/bjr.20170172] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Unterrainer M, Niyazi M, Tonn JC, Ilhan H, Bartenstein P, Albert NL. A look ahead: future directions of SSR-directed imaging and therapy in meningioma. Clin Transl Imaging 2019;7:357-62. [DOI: 10.1007/s40336-019-00333-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Jin X, Auernhammer CJ, Ilhan H, Lindner S, Nölting S, Maurer J, Spöttl G, Orth M. Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro. J Nucl Med 2019;60:1240-6. [DOI: 10.2967/jnumed.118.224048] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
3 Staanum PF, Frellsen AF, Olesen ML, Iversen P, Arveschoug AK. Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates. EJNMMI Phys 2021;8:78. [PMID: 34773508 DOI: 10.1186/s40658-021-00422-2] [Reference Citation Analysis]
4 Cives M, Pelle’ E, Quaresmini D, Mandriani B, Tucci M, Silvestris F. The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors. Curr Treat Options in Oncol 2019;20. [DOI: 10.1007/s11864-019-0669-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
5 Adant S, Shah GM, Beauregard J. Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2020;47:907-21. [DOI: 10.1007/s00259-019-04499-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
6 Telo S, Filice A, Versari A, Lamberti G, Campana D, Calabrò D, Fanti S, Ambrosini V. Peptide receptor radionuclide therapy for GEP-NET: consolidated knowledge and innovative applications. Clin Transl Imaging 2021;9:423-38. [DOI: 10.1007/s40336-021-00443-y] [Reference Citation Analysis]
7 Shah RG, Merlin MA, Adant S, Zine-Eddine F, Beauregard JM, Shah GM. Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of 177Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells. Cancers (Basel) 2021;13:E232. [PMID: 33435224 DOI: 10.3390/cancers13020232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ebbers SC, Heimgartner M, Barentsz MW, van Leeuwaarde RS, van Treijen MJC, Lam MMEG, Braat AJAT. Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study. Eur J Hybrid Imaging 2021;5:22. [PMID: 34881405 DOI: 10.1186/s41824-021-00116-z] [Reference Citation Analysis]
9 Thakral P, Sen I, Das SS, Manda D, Cb V, Malik D. Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease. Br J Radiol 2021;:20210403. [PMID: 34357794 DOI: 10.1259/bjr.20210403] [Reference Citation Analysis]
10 Malcolm J, Falzone N, Lee BQ, Vallis KA. Targeted Radionuclide Therapy: New Advances for Improvement of Patient Management and Response. Cancers (Basel) 2019;11:E268. [PMID: 30823564 DOI: 10.3390/cancers11020268] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
11 Özdirik B, Amthauer H, Schatka I, Goretzki PE, Mogl MT, Fehrenbach U, Tacke F, Jann H, Roderburg C. A rare case of a patient with a high grade neuroendocrine tumor developing neutropenic sepsis after receiving PRRT combined with Capecitabine or Temozolomide: A case report. Mol Clin Oncol 2021;14:20. [PMID: 33363730 DOI: 10.3892/mco.2020.2182] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Maharaj M, Heslop L, Govender T, Korowlay N, Singh A, Choudhary P, Sathekge M. The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer-a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report. Nucl Med Mol Imaging 2021;55:136-40. [PMID: 34093893 DOI: 10.1007/s13139-021-00696-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]